P

PacBio

Long-read DNA sequencing systems for genomics research

Principal Cybersecurity Engineer

Full-TimeUpdated
$195.9k - $293.9k
Expert
Bachelor's
Menlo Park, CA, USA
HybridOnsite Monday–Thursday and work from home Friday; occasional visits to other PacBio locations may be required.
CybersecuritySecurity Engineering & Architecture
No H1B Sponsorship

About the job

Requirements
  • A bachelor's degree in Computer Science, Information Security, Engineering, or a related field, or equivalent practical experience.
  • At least 12 years of experience in cybersecurity engineering, security architecture, or infrastructure security, including at least 5 years as a senior technical lead or architect responsible for security across enterprise environments.
  • Demonstrated experience serving as a technical lead for an ISO 27001 implementation, certification, or surveillance audit.
  • Experience designing, operating, and evidencing SOX IT general controls in a public company.
  • Deep hands-on expertise in network security architecture, including segmentation, next-generation firewalls, VPN/ZTNA, and secure remote access.
  • Experience securing enterprise and research storage, Linux-based HPC environments, and at least one major cloud platform (AWS, Azure, or GCP).
  • Hands-on experience hardening servers, endpoints, network devices, and IoT devices using CIS Benchmarks or equivalent baselines, supported by configuration management and vulnerability management tools.
  • Hands-on experience with modern EDR platforms (e.g., CrowdStrike, SentinelOne, Microsoft Defender) and SIEM, including leading security incidents end to end.
  • Proficiency in scripting and automation (Python, PowerShell, or Bash) and infrastructure as code (Terraform, Ansible).
  • Working knowledge of security frameworks such as NIST CSF, NIST SP 800-53, CIS Controls, and SOC 2.
  • Written and verbal communication skills, including the ability to explain risk clearly and influence engineers, executives, and auditors without direct authority.
  • Current authorization to work in the United States without the need for present or future sponsorship.
Responsibilities
  • Define and own PacBio's security architecture, standards, and multi-year engineering roadmap across enterprise, HPC, and cloud environments; prioritize work based on risk and track progress with clear, measurable outcomes.
  • Serve as technical lead for PacBio's ISO 27001 program: help define ISMS scope, conduct risk assessments, implement and evidence Annex A controls, maintain the Statement of Applicability, and lead preparation for internal, certification, and surveillance audits.
  • Own security-related IT general controls for financially significant systems, including logical access, privileged access, change management, and logging and monitoring; partner with Finance, Internal Audit, and external auditors on control design, testing, evidence, and timely remediation of deficiencies.
  • Own the security design of PacBio's networks, including segmentation, firewalls, secure remote and zero-trust access, wireless, and DNS and email security.
  • Secure large-scale research and enterprise storage through access controls, encryption, and data classification; design and regularly test controls to prevent, contain, and recover from disruptive cyberattacks, including immutable backups, recovery testing, and containment playbooks.
  • Secure HPC clusters and cloud environments (AWS, Azure, and/or GCP) supporting sequencing data analysis and R&D, including identity and privilege design, workload isolation, posture management, and security enforced through infrastructure as code.
  • Define and enforce secure configuration baselines (e.g., CIS Benchmarks) for Windows, macOS, and Linux endpoints and servers, hypervisors, network devices, and IoT devices; drive configuration compliance monitoring, vulnerability management, and patching with infrastructure and IT teams.
  • Strengthen identity and access controls across the enterprise, including SSO, MFA, privileged access management, and periodic access reviews.
  • Own EDR, SIEM, and MDR capabilities and related vendor relationships; tune detections for fidelity and coverage, lead response to significant security incidents, and run tabletop exercises and post-incident reviews.
  • Partner with R&D, Product Security, and Operations to secure connected sequencing instruments, IoT devices, and manufacturing and lab networks without disrupting production.
  • Automate security controls, audit evidence collection, and remediation using Python, Terraform, Ansible, or similar tools to make compliance continuous rather than periodic.
  • Lead technical responses to customer security questionnaires and reviews, and assess the security posture of key vendors and service providers.
  • Mentor IT and engineering staff on secure practices, direct the work of security vendors and contractors, and communicate risk, priorities, and progress to engineers, executives, and auditors.
  • Visit and work at PacBio locations as needed for proper performance of duties.
Desired Qualifications
  • Experience with secure software development practices, including secure SDLC, threat modeling, and integrating SAST, SCA, secrets scanning, and container security into CI/CD pipelines.
  • Experience in life sciences, genomics, biotech, medical devices, or another regulated industry, including protecting genomic or health data under HIPAA, GDPR, or CCPA/CPRA.
  • Experience securing connected devices, embedded systems, or OT and manufacturing environments.
  • Experience applying AI and LLM-driven automation to security operations, with appropriate human oversight and guardrails.
  • Certifications such as CISSP, CISM, CCSP, ISO 27001 Lead Implementer or Lead Auditor, GIAC, or a cloud security certification.

About the company

PacBio designs long-read DNA sequencing systems that help researchers read complete genomes, transcriptomes, and epigenomes. Its Revio and Vega platforms use proprietary HiFi sequencing chemistry, combining the completeness of long reads with the accuracy of short reads, supported by library prep kits, reagents, and the SMRT Link software suite. Specialized tools such as Kinnex for full-length RNA sequencing and PureTarget for targeted enrichment extend the platform into human genomics, oncology, microbial, agricultural, and biopharma research. What sets PacBio apart is its focus on accuracy and completeness over raw throughput, giving scientists confidence in genomic regions that short-read technologies often miss. The goal is to enable the promise of genomics to advance human health.

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 consumables rose 6% to $20.1 million as clinical shipments jumped 67%.
  • One-third of installed base opted into SPRQ-Nx by June, signaling adoption.
  • Vega SPRQ-Nx launches August 2026, expanding throughput and clinical market reach.

What critics are saying

  • Q2 2026 revenue stayed flat at $39 million; 2026 guidance fell to $155-$165 million.
  • Cash-flow breakeven slipped to 2028 after Christian Henry exited for Mark Van Oene.
  • Without SPRQ-Nx volume, PacBio burns cash, misses 2028 breakeven, and dilutes shareholders.

What makes PacBio unique

  • SPRQ-Nx on Revio cuts HiFi genome list price to $345, with multi-use SMRT Cells.
  • DNAstack and 30 institutions built a federated 10,000-plus HiFi rare-disease dataset.
  • GenomOncology integrated PacBio HiFi WGS into clinician-ready oncology reporting workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Company News

Yahoo Finance
Aug 6th, 2026
PacBio CEO steps down as revenue stalls at $39M and cash-flow breakeven pushed to 2028

Pacific Biosciences of California reported flat Q2 2026 revenue of $39 million whilst announcing a leadership change and revised outlook. CEO Christian Henry stepped down, with Mark Van Oene taking over immediately. Consumables revenue grew 6% to $20.1 million, driven by clinical customers whose shipments jumped 67% year-over-year. However, instrument revenue fell 9% to $12.8 million due to fewer Vega shipments and lower average selling prices. The company lowered its 2026 revenue forecast to $155 million–$165 million and delayed expected cash-flow breakeven to 2028. The revised outlook reflects slower adoption of its SMRT Next chemistry, which reduces sequencing costs by 30%, as customers validate the technology and work through existing reagent inventories. PacBio does not expect a significant consumables ramp until late 2026.

Associated Press
Jul 30th, 2026
GenomOncology and PacBio launch integrated long-read whole-genome sequencing workflow for oncology labs

GenomOncology, a precision oncology software company, has launched an integrated workflow for somatic whole-genome sequencing in oncology. The solution combines PacBio's HiFi WGS research-use-only secondary analysis pipeline with GenomOncology's Pathology Workbench platform to deliver standardised, clinician-ready reporting for clinical laboratories. The workflow addresses the challenge of translating long-read sequencing outputs into structured reports. It connects PacBio's pipeline, which handles analysis from raw sequencing through variant calls, with GenomOncology's platform for tertiary analysis, including quality control review, variant interpretation, and configurable report generation. A key feature is modular reporting architecture, enabling laboratories to derive tumour-specific sub-panels from shared WGS data whilst standardising upstream sequencing processes. The workflow can be deployed on-premises or on public cloud platforms. GenomOncology will present the workflow at the Cancer Genomics Consortium Annual Meeting in Houston from 1-5 August 2026.

Associated Press
May 26th, 2026
PacBio launches SPRQ-Nx chemistry enabling sub-$300 HiFi genomes with AI-enhanced sequencing

PacBio has begun worldwide shipping of its SPRQ-Nx sequencing chemistry and multi-use SMRT Cells for the Revio HiFi sequencing platform. The technology brings the per genome list price to $345, with the possibility of sub-$300 genomes for customers sequencing at scale. The company has enhanced its AI capabilities through updates to DeepConsensus, an algorithm developed with Google, including optimisations from Google's AlphaEvolve coding agent. PacBio is also advancing deep learning models for epigenetic detection, including updated methylation models and a new 5-hydroxymethyl-cytosine caller. Beta testing across 20 sites involving over 1,400 runs showed increased yield and lower failure rates compared to previous SPRQ chemistry. The improvements are available on existing Revio systems through software upgrades, with plans to bring SPRQ-Nx chemistry to the Vega benchtop system later in 2026.

Yahoo Finance
May 12th, 2026
PacBio shares drop 14% on revenue miss despite narrower Q1 loss

Pacific Biosciences of California saw its shares fall 14.2% after reporting mixed first-quarter 2026 results. The genomics company's revenue came in at $37.18 million, missing Wall Street's expectations of $40 million by over 7% and remaining flat year-on-year. While PacBio beat earnings expectations with an adjusted loss per share of $0.12 compared to the anticipated $0.13 loss, the revenue shortfall overshadowed this positive development. The company continues to face challenges including annualised revenue decline over the past two years, negative margins and significant cash burn. PacBio shares are down 24.7% year-to-date and trading at $1.39, 48.1% below their 52-week high of $2.67 from January 2026.

Yahoo Finance
May 7th, 2026
PacBio misses Q1 revenue estimates at $37.18M, flat year-on-year despite record consumables

Pacific Biosciences of California missed Q1 CY2026 revenue expectations, reporting sales of $37.18 million versus analyst estimates of $40 million, representing a 7.1% miss and flat year-on-year performance. The genomics company's non-GAAP loss of $0.12 per share beat consensus estimates by 8.7%. CEO Christian Henry noted record consumable revenue driven by increasing clinical adoption of HiFi sequencing, but instrument revenue, particularly for Vega, fell below expectations. The company's adjusted EBITDA was -$8.17 million with a -22% margin. Despite recent struggles, with revenue declining 10.6% annually over the past two years, analysts expect 12.6% growth over the next 12 months. PacBio has a market capitalisation of $530.9 million.